Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Saved in:
| Title: | Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. |
|---|---|
| Authors: | Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gerstein Y; Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bazinet A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tang G; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Quesada A; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel KP; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fiskus W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Mill CP; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Oran B; Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | American journal of hematology [Am J Hematol] 2023 Nov; Vol. 98 (11), pp. 1780-1790. Date of Electronic Publication: 2023 Sep 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-8652 |
|---|---|
| DOI: | 10.1002/ajh.27070 |
